European drugmakers call for faster trials, more spending to compete with US, China

European pharma chiefs warn region risks losing ground to America, China

Drugmakers for months have been warning they could curtail investments and delay the release of new medications in Europe, widening a disparity in access with the US, unless the region's healthcare systems agree to boost spending.

European drugmakers call for faster trials, more spending to compete with US, China

By Pushkala Aripaka LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical ​industry risks losing o...

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of Europe’s biggest pharmaceutical companies have said the continent is “losing ground” to rivals including the US and China in developing new drugs and attracting investment. The chairs of nine companies, including Britain’s AstraZeneca, GSK and Denmark’s Novo Nordisk, wrote to Andy Burnham…

Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report

Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.